Elfandy H, Armenia J, Pederzoli F, et al. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res. 2019;17(2):446-456. doi:10.1158/1541-7786.MCR-18-0440.

Currall BB, Chen M, Sallari RC, et al. Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet. 2018;27(24):4194-4203. doi:10.1093/hmg/ddy310.

Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018;128(10):4441-4453. doi:10.1172/JCI121924.

Tyekucheva S, Bowden M, Bango C, et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017;8(1):420. doi:10.1038/s41467-017-00460-4.

Golombos DM, Ayangbesan A, O’Malley P, et al. The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study. Urology. 2018;111:122-128. doi:10.1016/j.urology.2017.08.039.

Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8(10). doi:10.1101/cshperspect.a030569.

Miyahira AK, Sharp A, Ellis L, et al. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2020;80(2):113-132. doi:10.1002/pros.23934.

Ellis L, Loda M. LSD1: A single target to combat lineage plasticity in lethal prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4530-4531. doi:10.1073/pnas.1804205115.

Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453-457. doi:10.1038/nature23007.

Fei T, Chen Y, Xiao T, et al. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci U S A. 2017;114(26):E5207-E5215. doi:10.1073/pnas.1617467114.